Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Meta Platforms, Goldman Sachs And More On CNBC's 'Final Trades'

Author: Avi Kapoor | April 25, 2024 08:23am

On CNBC's “Halftime Report Final Trades,” Bryn Talkington of Requisite Capital Management named Sprott Uranium Miners ETF (NYSE:URNM) amid supply shortage here. The ETF has been basing in the 50's level and believes it is a “good entry point.”

Stephen Weiss of Short Hills Capital Partners picked Meta Platforms, Inc. (NASDAQ:META).

On Wednesday, Meta reported first-quarter revenue of $36.45 billion, which was up 27% year-over-year. The revenue came in ahead of a Street consensus estimate of $36.16 billion, according to data from Benzinga Pro. The company reported earnings per share of $4.71 in the first quarter, beating a Street estimate of $4.33.

Don't forget to check out our premarket coverage here

Joseph M. Terranova of Virtus Investment Partners said there is more upside ahead for The Goldman Sachs Group, Inc. (NYSE:GS).

On April 15, Goldman Sachs reported better-than-expected first-quarter earnings, posting revenue of $14.21 billion for the first quarter of 2024, beating the consensus of $12.92 billion. The Wall Street giant reported EPS of $11.58, beating the consensus of $8.60.

Global Banking & Markets were $9.73 billion, up 15% Y/Y, boosted by a 32% increase in investment banking fees to $2.08 billion, primarily driven by an increase in completed mergers and acquisitions transactions and initial public and secondary offerings.

Price Action:

  • Sprott Uranium Miners ETF fell 0.6% on Wednesday.
  • Meta shares fell 0.5% to settle at $493.50 during Wednesday's session.
  • Goldman Sachs fell 0.2% to close at $423.04 during Wednesday's session.

Check This Out: Jim Cramer Says You’re ‘Dice Rolling’ With This Biopharma Stock, But Vista Energy Is ‘A Good Situation’

Image: Shutterstock

Posted In: GS META URNM

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist